Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Exploring Three High Growth Tech Stocks in the United States

In This Article:

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high-growth tech stocks that can capitalize on such robust earnings growth potential becomes essential for investors seeking opportunities in a dynamic market environment.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

24.13%

24.28%

★★★★★★

Ardelyx

22.86%

54.70%

★★★★★★

AVITA Medical

33.33%

51.81%

★★★★★★

Alkami Technology

21.99%

102.65%

★★★★★★

AsiaFIN Holdings

51.75%

82.69%

★★★★★★

Alnylam Pharmaceuticals

21.39%

56.40%

★★★★★★

TG Therapeutics

30.33%

44.07%

★★★★★★

Clene

61.16%

59.11%

★★★★★★

Blueprint Medicines

22.61%

55.18%

★★★★★★

Travere Therapeutics

29.54%

61.86%

★★★★★★

Click here to see the full list of 226 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Mirum Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $1.98 billion.

Operations: Mirum Pharmaceuticals focuses on developing and commercializing therapies for rare and orphan diseases, generating $307.03 million in revenue from its pharmaceuticals segment.

Mirum Pharmaceuticals, despite its current unprofitability, is navigating a promising trajectory with expected revenue growth at 23.7% annually, outpacing the broader US market's 9%. This growth is underpinned by robust forecasts that see the company turning profitable within three years—a notable achievement given the industry's competitive intensity. Recent guidance for 2025 projects net product sales reaching up to $435 million, reflecting confidence in sustained demand for their biotechnological innovations. Additionally, Mirum's active participation in key medical conferences underscores its commitment to advancing liver disease treatment, enhancing its visibility and credibility within the biotech sector.

NasdaqGM:MIRM Revenue and Expenses Breakdown as at Jan 2025
NasdaqGM:MIRM Revenue and Expenses Breakdown as at Jan 2025

Enfusion

Simply Wall St Growth Rating: ★★★★★☆

Overview: Enfusion, Inc. offers software-as-a-service solutions tailored for the investment management industry across various regions including the United States, Europe, the Middle East, Africa, and Asia Pacific, with a market capitalization of approximately $1.39 billion.